((自动化翻译由路透提供，请见免责声明 ))
路透1月10日 - Royalty Pharma 周五表示，它将支付约11亿美元收购RP Management公司。
Royalty Pharma 向学术实验室和生物技术公司购买未来药物的特许权使用费，而这些公司则用现金资助自己的研究。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.